Cost-Effectiveness of Local Therapies for Inoperable, Localized Hepatocellular Carcinoma

被引：0
|
作者：
Pollom, E. [1 ]
Lee, K. [2 ,3 ]
Durkee, B. Y. [4 ]
Grade, M. [5 ]
Mokhtari, D. [5 ]
Weeks, B. [5 ]
Feng, M. [6 ]
Wahl, D. R. [6 ]
Kothary, N.
Koong, A. C. [1 ]
Owens, D. [2 ,3 ]
Goldhaber-Fiebert, J. [2 ,3 ]
Chang, D. T. [7 ]
机构：
[1] Stanford Canc Inst, Dept Radiat Oncol, Stanford, CA USA
[2] Stanford Ctr Hlth Policy, Palo Alto, CA USA
[3] Stanford Ctr Primary Care & Outcomes Res, Palo Alto, CA USA
[4] Stanford Canc Inst, Stanford, CA USA
[5] Stanford Sch Med, Palo Alto, CA USA
[6] Univ Michigan, Ann Arbor, MI 48109 USA
[7] Stanford Univ, Dept Radiat Oncol, Sch Med, Stanford, CA 94305 USA
来源：
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2016年 / 96卷 / 02期
关键词：
D O I：
10.1016/j.ijrobp.2016.06.938
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2337
引用
收藏
页码：E138 / E138
页数：1
相关论文
共 50 条
  • [1] The cost-effectiveness of new first-line therapies approved in advanced hepatocellular carcinoma
    Giuliani, Jacopo
    Mantoan, Beatrice
    Bonetti, Andrea
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2022, 28 (02) : 434 - 437
  • [2] Transarterial therapies in patients with hepatocellular carcinoma eligible for transarterial embolization: a US cost-effectiveness analysis
    Patel, Mikin V.
    Davies, Heather
    Williams, Abimbola O.
    Bromilow, Tom
    Baker, Hannah
    Mealing, Stuart
    Holmes, Hayden
    Anderson, Nicholas
    Ahmed, Osman
    JOURNAL OF MEDICAL ECONOMICS, 2023, 26 (01) : 1061 - 1071
  • [3] Screening for hepatocellular carcinoma: survival benefit and cost-effectiveness
    Yuen, MF
    Lai, CL
    ANNALS OF ONCOLOGY, 2003, 14 (10) : 1463 - 1467
  • [4] COST-EFFECTIVENESS OF LENVATINIB IN THE TREATMENT OF HEPATOCELLULAR CARCINOMA IN THE UK
    Simon, C.
    Trueman, D.
    Hancock, E.
    Hellmund, C.
    Pan, J. J.
    de Rosendo, J. M.
    Webb, T.
    VALUE IN HEALTH, 2019, 22 : S478 - S478
  • [5] Cost-Effectiveness Analysis of Curative Therapies for Early Stage Hepatocellular Carcinoma (HCC) within Milan Criteria
    Maegawa, Felipe A.
    Al Hadidi, Samer S. A.
    Limsrivilai, Julajak
    Chum, Marvin
    Kettelle, John B.
    Riall, Taylor S.
    JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 2017, 225 (04) : E28 - E28
  • [6] Cost-effectiveness of biological therapies
    Feetham, Laura
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2019, 4 (05): : 337 - 337
  • [7] Cost-effectiveness of therapies for melanoma
    Johnston, Karissa M.
    McPherson, Emily
    Osenenko, Katherine
    Vergidis, Joanna
    Levy, Adrian R.
    Peacock, Stuart
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2015, 15 (02) : 229 - 242
  • [8] Cost-effectiveness of antiplatelet therapies
    Schleinitz, MD
    ARCHIVES OF INTERNAL MEDICINE, 2001, 161 (09) : 1236 - 1236
  • [9] COST-EFFECTIVENESS OF MODERN THERAPIES
    Leighl, Natasha
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S88 - S88
  • [10] ASSESSING THE COST-EFFECTIVENESS OF THERAPIES IN THE THIRD QUADRANT ON THE COST-EFFECTIVENESS PLANE
    Nemeth, B.
    Eder, B.
    VALUE IN HEALTH, 2015, 18 (07) : A562 - A562
12345